• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

    10/30/24 12:55:00 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors

    Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/

    Adam Herbst (Photo: Business Wire)

    Adam Herbst (Photo: Business Wire)

    In joining Sheppard Mullin's industry-leading Healthcare team, Herbst specializes in healthcare policy, Medicaid reform and corporate governance, with a strong focus on transforming healthcare systems to ensure equitable access and improved quality for diverse populations, including children, seniors and individuals with disabilities.

    As Deputy Commissioner for Aging and Long Term Care at the Department of Health, Herbst oversaw regulation for the state of New York's acute care, post-acute care, disability and long-term care industries. As an advisor to the Governor of New York, he led state and federal policy and fiscal initiatives, including the Governor's Master Plan for Aging commission, the Medicaid 1115 research and demonstration waiver, federal value-based care initiatives, managed care reform and social care integration strategies.

    He served as the Commissioner's Special Advisor where he developed and implemented comprehensive policies and programs aimed at strengthening New York's health systems and payors. His efforts addressed the diverse needs of communities statewide, particularly in the wake of COVID-19, ensuring that all New Yorkers had equitable access to quality healthcare services. Adam's initiatives spanned various demographics, focusing on improving health outcomes and enhancing service delivery for vulnerable populations, including aging individuals, those with disabilities and other underserved communities. He has also implemented initiatives that incentivize healthcare providers to deliver high-value services, particularly for dual-eligible individuals who often face complex healthcare challenges.

    In addition to his regulatory and policy work, Herbst has a strong transactional background, having been involved in numerous mergers and acquisitions within the healthcare sector. He has a proven track record of facilitating partnerships and collaborations that enhance service delivery and operational efficiency. His advocacy for integrated care models fosters collaboration among providers to improve care coordination and patient outcomes. With decades of healthcare regulatory expertise, Herbst is adept at creating alignment strategies for Medicare, Medicaid and other government payer programs.

    "Adam is a nationally recognized leader in the healthcare industry, and we are delighted to welcome him to the firm." said Luca Salvi, chair of Sheppard Mullin. "His multi-dimensional understanding of the marketplace and deep knowledge advising healthcare companies through strategic investments will be invaluable to our clients."

    Eric Klein, leader of the firm's Healthcare industry team added, "The aging population is fueling significant opportunities in the post-acute care sector, including the expansion of existing and creation of new providers, funding and regulation. Adam's reputation and exceptional experience further cements Sheppard Mullin's as the destination for top-tier regulatory and compliance counsel across the aging, hospital care and long-term care sectors."

    "The regulatory landscape for post-acute care providers is complex and ripe for change," added Herbst. "I was drawn to the size and reputation of Sheppard Mullin's nationally known, comprehensive healthcare practice. The attorneys and resources at the firm will allow me to continue providing innovative advice to clients as we navigate the evolving healthcare environment."

    Sheppard Mullin has one of the country's most active long-term care and post-acute care practices, representing all segments of this industry. Recent examples include:

    • Represented private equity firm Clayton, Dubilier & Rice in forming a multibillion-dollar strategic partnership with Elevance Health, Inc. (NYSE:ELV). One of the two largest healthcare services transactions in 2024, the deal launched a new advanced primary care solution that streamlines the patient experience, improves health outcomes and lowers healthcare costs, particularly for the senior population.
    • In one of the largest home health and hospice transactions of the year, Sheppard Mullin is representing leading home-based care service provider, Compassus, in its joint venture with nonprofit health system Providence that will offer home health, hospice and palliative care to patients across Alaska, California, Oregon, Washington and Texas.
    • Advised AccentCare, nationwide post-acute healthcare services leader, in several transactional, regulatory and financing matters, including its acquisition of and joint venture with Memorial Hermann's home health and hospice operations; joint venture with and acquisition of Fairview health system's home health and hospice line of business; home health and hospice joint venture with Baylor Scott & White Health, the largest not-for-profit health system in Texas; and joint ventures with University of California, San Diego and the University of California, Los Angeles.
    • Advised post-acute and specialty home health provider Collage Rehabilitation Partners in its acquisition of Omicron Care, a home health provider to patients with catastrophic injuries including, stroke and neurologic disorders. The acquisition expanded Collage's national continuum of care in new and existing markets.

    Herbst received his B.A., summa cum laude, from American University, his J.D. from Albany Law School, and his M.B.A. from Union College. He is a frequent speaker on healthcare access and technology and currently serves as an adjunct professor at Columbia University's Mailman School of Public Health and at New York Law School, teaching health policy and bioethics.

    About Sheppard Mullin's Healthcare Team

    Sheppard Mullin's 260-attorney national healthcare industry team has been named a Health Care Practice Group of the Year by Law360 three times in seven years. Working in all sectors of healthcare with industry-leading and growing companies, disruptive start-up clients and healthcare-focused investors, Sheppard Mullin is a go-to firm for innovative transactions and joint ventures, regulatory solutions, population health management, global risk and value-based contracting, technology transactions and privacy matters. The team offers significant experience in cybersecurity, tax, non-profit, employment and labor, real estate, artificial intelligence, antitrust, litigation and finance.

    About Sheppard, Mullin, Richter & Hampton LLP

    Sheppard Mullin is a full-service AmLaw 50 firm with more than 1,100 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, industry-leading companies have turned to Sheppard Mullin to handle corporate and technology matters, high-stakes litigation and complex financial transactions. In the U.S., the firm's clients include nearly half of the Fortune 100. For more information, please visit www.sheppardmullin.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241030758975/en/

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has recently joined Sheppard Mullin and what is their area of specialization?

      Adam Herbst has joined Sheppard Mullin as a healthcare partner who specializes in healthcare policy, Medicaid reform, and corporate governance, strengthening the firm's capabilities in the post-acute, aging, and long-term care sectors.

    • What was Adam Herbst's previous role before joining Sheppard Mullin?

      Herbst previously served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care, where he oversaw regulations for various healthcare sectors.

    • What specific focus areas does Adam Herbst emphasize in his work in healthcare policy?

      He focused on transforming healthcare systems to ensure equitable access and improved quality for populations such as children, seniors, and individuals with disabilities.

    • What kind of experience does Adam Herbst bring to Sheppard Mullin in relation to healthcare transactions?

      He has extensive experience in facilitating partnerships and collaborations that enhance service delivery in the healthcare sector, along with a strong transactional background.

    • What distinguishes Sheppard Mullin's healthcare team within the industry?

      Sheppard Mullin has one of the country's most active long-term care and post-acute care practices, which has advised on significant transactions like the partnership between Clayton, Dubilier & Rice and Elevance Health.

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    4/8/2026$345.00In-line
    Evercore ISI
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    More analyst ratings

    $ELV
    SEC Filings

    View All

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 11:27:18 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 6:01:33 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/15/26 4:10:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance

    1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

    4/22/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care